UK markets open in 42 minutes

LadRx Corporation (0I5R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0000-1.4600 (-59.35%)
At close: 06:49PM BST

LadRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310 826 5648
https://www.ladrxcorp.com

Sector(s)
Industry
Full-time employees2

Key executives

NameTitlePayExercisedYear born
Dr. Stephen Snowdy Ph.D.Chief Executive Officer545kN/A1970
Mr. John Y. CalozCFO, Treasurer Senior VP & Corporate Secretary416kN/A1952
Molly Carey PoarchGlobal & U.S. Head of Corporate CommunicationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent which targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.

Corporate governance

LadRx Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.